A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | 17M | - |
| Net Income | -156M | -156M | -102M | -170M | - | -130M |
| EPS | $-2.35 | $-2.35 | $-1.81 | $-2.96 | $2.79 | $-3.40 |
| Free Cash Flow | -136M | -136M | -64M | -135M | -196M | -110M |
| ROIC | -12.1% | -20.8% | -59.0% | -137.1% | -117.9% | -128.4% |
| Gross Margin | - | - | - | - | 89.9% | - |
| Debt/Equity | 0.05 | 0.05 | 0.06 | 0.65 | 0.87 | 0.14 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -184M | -184M | -83M | -118M | -124M | -96M |
| Operating Margin | 0.0% | - | - | - | -722.6% | - |
| ROE | -12.5% | -21.1% | -59.0% | -129.5% | - | -69.4% |
| Shares Outstanding | 66M | 66M | 57M | 58M | - | 38M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | N/A | N/A | 17M | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | 89.9% | N/A | N/A | N/A | N/A |
| R&D | 69M | 84M | 92M | 92M | 87M | 100M | 133M | 133M |
| SG&A | 6.9M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | N/A | -88M | -96M | -124M | -118M | -83M | -184M | -184M |
| Op. Margin | N/A | N/A | N/A | -722.6% | N/A | N/A | N/A | 0.0% |
| Net Income | 92M | -86M | -130M | N/A | -170M | -102M | -156M | -156M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | N/A | -154.7% | -128.4% | -117.9% | -137.1% | -59.0% | -20.8% | -12.1% |
| ROE | 52.1% | -47.2% | -69.4% | N/A | -129.5% | -59.0% | -21.1% | -12.5% |
| ROA | N/A | -35.7% | -51.0% | N/A | -62.3% | -40.5% | -18.8% | -11.3% |
| Cash Flow | ||||||||
| Op. Cash Flow | -73M | -61M | -106M | -192M | -133M | -62M | -135M | -135M |
| Free Cash Flow | -74M | -65M | -110M | -196M | -135M | -64M | -136M | -136M |
| Owner Earnings | -73M | -61M | -106M | -192M | -133M | -62M | -135M | -135M |
| CapEx | 639K | 3.2M | 3.9M | 3.5M | 1.7M | 1.6M | 1.5M | 1.5M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.5M |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 4.5M | 0 | 6.1M | 51M | 51M |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 62M | 77M | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | -138M | -121M | -51M | -77M | -50M | -48M | -48M |
| Cash & Equiv. | 136M | 162M | 148M | 179M | 151M | 65M | 105M | 105M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | 41M | 41M |
| Debt/Equity | N/A | 0.13 | 0.14 | 0.87 | 0.65 | 0.06 | 0.05 | 0.05 |
| Interest Coverage | N/A | -173.4 | -12.7 | -49.7 | -3.1 | -3.0 | -24.7 | -24.7 |
| Equity | 177M | 186M | 189M | 147M | 115M | 232M | 1.2B | 1.2B |
| Total Assets | N/A | 240M | 271M | 328M | 218M | 288M | 1.4B | 1.4B |
| Total Liabilities | N/A | 53M | 82M | 181M | 102M | 56M | 129M | 129M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | 1.8M | 1.8M |
| Retained Earnings | N/A | -216M | -353M | 138M | -590M | -712M | -892M | -892M |
| Working Capital | N/A | 185M | 164M | 220M | 159M | 218M | 1.2B | 1.2B |
| Current Assets | N/A | 214M | 219M | 273M | 186M | 259M | 1.2B | 1.2B |
| Current Liabilities | N/A | 29M | 55M | 53M | 28M | 41M | 58M | 58M |
| Per Share Data | ||||||||
| EPS | 3.00 | -2.54 | -3.40 | 2.79 | -2.96 | -1.81 | -2.35 | -2.35 |
| Owner EPS | -2.38 | -1.82 | -2.77 | N/A | -2.32 | -1.10 | -2.03 | -2.03 |
| Book Value | 5.75 | 5.51 | 4.94 | N/A | 2.01 | 4.10 | 18.79 | 18.79 |
| Cash Flow/Share | -2.38 | -1.82 | -2.77 | N/A | -2.32 | -1.10 | -2.03 | -2.35 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 30.7M | 33.8M | 38.4M | N/A | 57.5M | 56.6M | 66.4M | 66.4M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -122.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 15.3 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.7% |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.1B |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 287.80 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 287.80 |
ZEALAND PHARMA A/S passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 89.9%. Total shareholder yield (buybacks) is 0.3%.
ZEALAND PHARMA A/S (ZEAL-CO) has a 5-year average return on invested capital (ROIC) of -92.6%. This is below average and may indicate limited pricing power.
ZEALAND PHARMA A/S (ZEAL-CO) has a market capitalization of $19.1B. It is classified as a large-cap stock.
ZEALAND PHARMA A/S (ZEAL-CO) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.27%.
ZEALAND PHARMA A/S (ZEAL-CO) generated $-136 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ZEALAND PHARMA A/S (ZEAL-CO) has a debt-to-equity ratio of 0.05. This indicates a conservatively financed balance sheet.
ZEALAND PHARMA A/S (ZEAL-CO) reported earnings per share (EPS) of $-2.35 in its most recent fiscal year.
ZEALAND PHARMA A/S (ZEAL-CO) has a return on equity (ROE) of -21.1%. A negative ROE may indicate losses or negative equity.
ZEALAND PHARMA A/S (ZEAL-CO) has a 5-year average gross margin of 89.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for ZEALAND PHARMA A/S (ZEAL-CO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ZEALAND PHARMA A/S (ZEAL-CO) has a book value per share of $18.79, based on its most recent annual SEC filing.